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Individuals with mosaicism for the autosomal dominant bone dysplasia osteogenesis imperfecta (OI) are generally
identiﬁed by having more than one affected child. The mosaic carriers have both normal and mutant cell populations
in somatic and germline tissues but are unaffected or minimally affected by the type I collagen mutation that
manifests clinically in their heterozygous offspring. We determined the proportion of mutant osteoblasts in skeletal
tissue of two mosaic carriers who each have a COL1A1 mutation in a high proportion of dermal ﬁbroblasts. Both
carriers had normal height and bone histology; the ﬁrst carrier had normal lumbar spine measurements (L1–L4),
as determined by dual-energy x-ray absorptiometry (Z p +1.17). In cultured cells from the ﬁrst carrier, studied by
labeled PCR and single-cell PCR over successive passages, the collagen mutation was present in 85% of ﬁbroblasts
and 50% and 75% of osteoblasts from her right iliac crest and left patella, respectively, with minimal selection.
The second carrier was studied by PCR ampliﬁcation of DNA from autopsy parafﬁn blocks. The proportion of
heterozygous cells was 40% in calvarium, 65% in tracheal ring, and 70% in aorta. Thus, in OI, substantially
normal skeletal growth, density, and histology are compatible with a 40%–75% burden of osteoblasts heterozygous
for a COL1A1 mutation. These data are encouraging for mesenchymal stem-cell transplantation, since mosaic
carriers are a naturally occurring model for cell therapy.
Most cases of osteogenesis imperfecta (OI), or “brittle
bone disease,” are caused by mutations in one of the
two genes encoding type I collagen, the major structural
component of the matrix of bone and skin (Byers and
Cole 2002). Affected individuals have fragile bones and
increased susceptibility to fractures (Marini and Cher-
noff 2001). Collagen mutations causing this bone dys-
plasia occur in two broad categories (Byers et al. 1991),
structural defects and quantitative defects. Structural de-
fects of the alpha chains are associated with the lethal,
severe, and moderate forms of the disease (type II [MIM
166210], type III [MIM 259420], and type IV [MIM
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166220], respectively). The quantitative defects are usu-
ally caused by a null COL1A1 allele (Willing et al.
1994), resulting in a reduced amount of structurally nor-
mal collagen and mild symptoms (OI type I [MIM
166200]).
Dominant negative mutations, such as collagen struc-
tural defects, will not be amenable to the gene-replace-
ment approach that is being developed as therapy for
recessive disorders (Marini and Gerber 1997). The gene-
replacement approach aims to transfer a construct con-
taining a normal gene into the tissue of a patient who
has no functional product from the endogenous copies
of the gene. Even modest expression of the construct
might provide sufﬁcient gene product for clinical cor-
rection. In OI types II, III, and IV, the defective collagen
is secreted from the cell and incorporated into the ma-
trix, where it actively contributes to a weakened struc-
ture. Furthermore, depending on whether the structural
defect is in the a1 or a2 chain of type I collagen, the
heterotrimeric procollagen secreted from the cell can in-
clude 75% or 50% abnormal helices, respectively. The
addition of a modest amount of normal collagen from
an expression construct would not be sufﬁcient to coun-
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teract the dominant negative function of the endogenous
mutant collagen. One approach to therapy for OI and
other dominant skeletal dysplasias involves the trans-
plantation of normal mesenchymal precursors (Niyibizi
et al. 2002). The naturally occurring model for this ap-
proach is the mosaic carrier. This individual has two
genetically distinct cell lines, one of which carries the
disease-causing mutation because of a postzygotic event
(Hall 1988). Almost two dozen mosaic carriers for OI
have been molecularly delineated (Dalgleish 1997,
1998). Most carriers described in the literature have had
children with lethal OI; a recurrence risk of 5%–7% has
been estimated for lethal OI (Byers et al. 1988). Lund
and colleagues have reported ﬁve parental mosaic car-
riers for moderate-to-severe nonlethal OI (Lund et al.
1996, 1997, 1999), suggesting that mosaicism occurs in
at least a similar proportion of nonlethal mutations.
Clinically, the mosaic carriers are normal or minimally
affected. They are most often identiﬁed by having more
than one child with the fully manifesting heterozygous
condition.
In each mosaic carrier, the proportion of mutant cells
varies from tissue to tissue. The proportions will depend
on the postzygotic timing of the collagen mutation and
its relationship to the development of the embryo, in-
cluding the tissues to which the daughters of the original
mutant cell contribute and the distribution of the mutant
cell line within those tissues. Selective pressures may also
play a variable role in different tissues. For example, the
mutation might affect cell replication and senescence dif-
ferently in tissues in which the mutant gene was not
expressed than in those with high or low expression
levels. In 10 mosaic carriers of OI, the proportion of
mutant cells was determined in more than one tissue by
examining ﬁbroblasts, leukocytes, hair bulbs, and
sperm, as available. In each carrier, there was wide var-
iation in the proportion of mutant cells between tissues.
For example, a mosaic carrier of a nonlethal mutation
(COL1A2 G802D), which caused OI type III/IV in the
individual’s affected offspring, had 25% mutant alleles
in leukocytes and 40% mutant alleles in sperm (Lund
et al. 1996). Three carriers had a collagen mutation in
at least half of their leukocytes and essentially all of their
ﬁbroblasts (Constantinou et al. 1989; Wallis et al. 1990;
Edwards et al. 1992).
The proportion of mutant osteoblasts that is com-
patible with normal skeletal functioning is clearly crucial
but has not been examined in mosaic carriers. This data
cannot be estimated by extrapolation because of tissue-
to-tissue variation. The relative survival, over successive
passages, of bone and skin cells carrying a collagen mu-
tation, as compared with normal cells from the same
individual, also has not been reported.
We have determined the proportion of mutant oste-
oblasts and ﬁbroblasts in twomosaic carriers ofOI. Each
mosaic carrier has a structural mutation in the a1 chain
of type I collagen, which causes OI type III or IV in the
children of the carrier. This information about naturally
occurring mosaic carriers provides target levels for cell
therapy.
The ﬁrst mosaic carrier is a 51-year-old woman whose
two sons have moderately severe OI type IV. She has
had mild functional effects from the collagen mutation
she carries, compatible with an OI type I phenotype.
Her height is 160 cm, which is in the 25th percentile for
adult women but which is 8 cm less than the height
predicted by parental heights. Her 168-cm span is mod-
erately longer than her height and her upper segment to
lower segment ratio of 0.82 is 12 SDs below average
for adult women and conﬁrms that her slightly short
stature is associated with a short trunk. Head circum-
ference is relatively large (57 cm; 95th percentile for
adult women). She has light blue sclerae. Dentinogenesis
imperfecta was detected on her Panorex, although it is
not apparent on oral inspection. Wormian bones were
detected by radiography on a lateral skull ﬁlm. Lumbar
spine (L1–L4), as measured by dual-energy x-ray ab-
sorptiometry (DEXA), is in the normal range (1.083 gm/
cm2; ), without prior administration of bis-Zp 1.17
phosphonates. She sustained two fractures from minor
accidents, a fractured wrist at age 13 years in a bicycle
fall and a shattered left patella at age 46 years from a
fall in the bathroom at home. Moderately severe low-
frequency conductive hearing loss (R 30 dB; L 50 dB)
developed in her 40s, without external risk factors such
as noise exposure, but she does not require ampliﬁcation.
Her sons developed hearing loss in their 20s. Her skin
thickness and elasticity are normal, with well-healed sur-
gical scars. Both large and small joints have normal
mobility.
The type I collagen mutation causing OI type IV in
her sons was determined to be a COL1A1 intron 19
G1rC point mutation by conformation-sensitive gel
electrophoresis (Korkko et al. 1998) of PCR ampliﬁ-
cation (Saiki et al. 1985) products, followed by sequenc-
ing (Sanger et al. 1977) on a Prism 377 DNA Sequencer
(Applied Biosystems) by the Center for Gene Therapy,
Tulane University, New Orleans. The mutation intro-
duces a DdeI restriction site, which was detected in a
PCR ampliﬁcation product spanning COL1A1 introns
15–19 of the mosaic carrier’s dermal ﬁbroblast and leu-
kocyte genomic DNA. The mutation causes skipping of
exon 19 at the cDNA level (ﬁg. 1A and 1B); RT-PCR
ampliﬁcation of total ﬁbroblast RNA (Chomczynski and
Sacchi 1987) of one of the affected sons showed that
about half of the transcripts of the mutant allele have
exon 19 skipping (data not shown).
Skin ﬁbroblast cultures of the mosaic carrier and her
son were established from dermal punch biopsies. Os-
teoblast primary cultures were established from surgical
754 Am. J. Hum. Genet. 74:752–760, 2004
Figure 1 Collagen mutation and clonal lines of the mosaic carrier of OI type IV. A, Sequence of the normal and mutant cDNA of son
of the mosaic carrier, showing skipping of COL1A1 exon 19 sequences. B, Sequence of COL1A1 gene, showing the splice-donor–site mutation
IVS 19 G1rC. C, Demonstration that the mosaic carrier has two distinct cell lines. The PCR fragment containing the exon 19/intron 19
junction was ampliﬁed fromDNA of dermal ﬁbroblast clonal lines by PCR, by use of a forward primer in exon 19 (5′-TGCTCCTGGTATTGCTG-
GTGCTCCTGGCTTC-3′) and a reverse primer in intron 19 (5′-gcgtcttcctgctccccagatgagagccgc-3′) (lowercase letters denote intron nucleotides;
uppercase letters denote exon nucleotides). PCR conditions were 94C for 5 min; 30 cycles of 1 min at 94C, 30 s at 67C, and 30 s at 72C;
and, ﬁnally, 7 min at 72C. Ampliﬁcation products were digested with DdeI and electrophoresed on a 6% acrylamide gel. Five clonal lines (2,
3, 6, 7, 8) have undigested product (174 nt) from normal allele sequence and 6 clonal lines (1, 4, 5, 9, 10, 11) are heterozygous for normal
and mutant allele products (DdeI digestion products, 97 nt and 77 nt). S is the 50-bp ladder; N and H are normal and heterozygous control
cells.
bone chips (Robey and Termine 1985). Bone chips from
the mosaic carrier of OI type IV were obtained from a
left patella repair and a right iliac crest biopsy; bone
chips from her son were obtained at osteotomy. All sam-
ples were obtained with informed consent of the carrier
and the assent of her son.
The collagen mutation was estimated to be present in
72% of maternal leukocytes, by densitometry of DdeI
digestion products of a 32P-labeled PCR fragment that
included the exon 19/intron 19 junction. The existence
of two distinct cell populations demonstrated that the
individual was a true mosaic carrier for the mutation.
From the dermal ﬁbroblasts of the mosaic carrier, 11
clonal lines were generated. Dilute low-passage ﬁbro-
blasts were distributed in 96-well plates; wells with sin-
gle cells were identiﬁed by microscopic inspection.When
sufﬁcient numbers of cell divisions had occurred, the
clonal cells were transferred successively to 24-well, 12-
well, and 6-well plates, at which time their DNA was
isolated using the PureGene DNA Isolation Kit (Gentra
Systems). PCR of clonal genomic DNA followed byDdeI
digestion identiﬁed six lines with the IVS19 G1rC mu-
tation and with ﬁve normal collagen sequences (ﬁg. 1C).
The proportion of ﬁbroblasts and osteoblasts hetero-
zygous for the collagen mutation was quantitated by
both (1) a radiolabeled PCR assay using total genomic
DNA and (2) a single-cell PCR ampliﬁcation of the re-
gion surrounding the point mutation. The accuracy of
both assays was validated by use of DNA and cells from
the heterozygous son of the carrier. For the radiolabeled
PCR assay, a 174-bp region of COL1A1 genomic DNA
was ampliﬁed using primers located in exon 19 and in-
tron 19 and 5 mCi of 111 TBq/mmol [a-32P] dCTP. PCR
products were digested with DdeI. Digestion products
were quantitated by densitometry of autoradiograms.
Allele proportions from the mosaic-carrier samples were
normalized to allele detection in heterozygous samples.
Triplicate PCR reactions were analyzed for each person
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Table 1
Fibroblast Results from 32P-Labeled PCR Assay of Samples
from the Mosaic Carrier of OI Type IV and Affected Son
PASSAGE
NO.
% OF FIBROBLASTS HETEROZYGOUS FOR




Left Side Right Side
P2–P7 96  4 83  8 (86) 82  6 (85)
P13 95  4 81  13 (85) 82  6 (86)
P17 95  3 80  4 (84) 84  5 (88)
P20 92  5 74  4 (80) 70  7 (76)
Genomic DNA of COL1A1 was ampliﬁed for exon 19–
intron 19 (174 bp).
a Value calculated by densitometry of DdeI-digested PCR
fragments as follows: digested fragments/total fragments#
2 # 100.
Table 2
Fibroblast Results from Single-Cell PCR Assay of Samples from the Mosaic Carrier of OI Type IV and Affected Son
NO. OF CELLS DETECTED IN
Mosaic Carrier
Heterozygous Affected Son Left Side Right Side
PASSAGE NO. Normal Mutant Heterozygous Total %a Normal Mutant Heterozygous Total % Normal Mutant Heterozygous Total %
P6–10 6 6 93 105 94.3 25 2 81 108 82.4 23 2 88 113 85.0
P 20 8 4 94 106 92.5 37 3 74 114 75.4 39 0 61 100 69.0
a Percentage of heterogeneous cells plus mutant cells, divided by the total number of cells. (In the mosaic carrier, this number has been normalized for false-
normal cells in the affected son.)
at each passage. The labeled PCR yielded estimates of
90%–96% heterozygous cells, compared with the ex-
pected 100% heterozygous cells in the son.
The assay for quantitating the proportion of hetero-
zygous cells in the mosaic carrier by single-cell PCR was
modiﬁed from the procedure used by Leeﬂang et al.
(1995). Cells were plated in 96-well plates at an average
of 1 cell/well, with ∼25%–30% of wells containing a
single cell. Wells with individual cells were identiﬁed by
microscopic examination the following morning, lysed
in the well, and the entire single-cell lysate was used for
a heminested PCR. First-round ampliﬁcations used 100
mM 7-deaza-dGTP, 10% glycerol, 3% DMSO, 100 mg/
ml gelatin, and 1 U rTth DNA polymerase (Perkin El-
mer). The sense primer for ﬁrst-round ampliﬁcation
spanned the COL1A1 intron 18/exon 19 junction (5′-
acagGGTGCTCCTGGTATTGCTGG-3′ [lowercase let-
ters denote intron nucleotides; uppercase letters denote
exon nucleotides]) and the antisense primer was in intron
19. Second-round ampliﬁcations used 10% glycerol, 3%
DMSO, 100 mg/ml gelatin, 1 U of Taq DNA polymerase,
and 5 ml of ﬁrst-round PCR product. The sense primer
for the second round was in exon 19 (5′-GTGCCCGAG-
GCCCCCTCTGGA-3′), and the antisense primer was
identical to ﬁrst round ampliﬁcation. All PCR conditions
are available from the authors upon request. The entire
second-round PCR reaction was concentrated in Micro-
con YM-30 spin columns (Millipore), digested with
DdeI, electrophoresed on a 6% polyacrylamide gel, and
visualized by ethidium bromide staining. Heterozygosity
of an individual cell was determined by the presence of
both alleles in the PCR product. The proportion of het-
erozygous cells in the mosaic carrier was normalized for
the low percentage of false-normal PCRs of heterozy-
gous control cells in which only the normal allele was
ampliﬁed. In the affected heterozygous son of the mosaic
carrier, single-cell PCR detected 93% of heterozygous
ﬁbroblasts and 88% of heterozygous osteoblasts. The
small false-normal background occurs in the assays of
single heterozygous cells because of physical loss of the
single copy of the normal allele or its failure to amplify
in the early cycles of the PCR. The raw values of the
mosaic carrier assays were corrected for the detection
level in the heterozygous samples.
The use of these assays on carrier ﬁbroblast DNA (ta-
bles 1 and 2) yielded consistent estimates of 86%mutant
ﬁbroblasts by labeled PCR and 85% mutant ﬁbroblasts
by single-cell PCR, persisting in passages 2–17. The pro-
portion was similar on both sides of the carrier’s body,
with only mild selection against mutant cells at high pas-
sage. Cultured osteoblasts (tables 3 and 4) from the right
and left sides of her body had different proportions of
mutant cells. On the left, she had 73% mutant cells, as
determined by both labeled PCR and single-cell PCR. In
the right iliac crest sample, 50% mutant cells were de-
tected by labeled PCR, in agreement with 48% mutant
cells detected by single-cell PCR. The proportion of mu-
tant osteoblasts was stable throughmediumpassage num-
bers and fell only at high passage numbers (P10). We are
unable to comment on any selection against mutant os-
teoblasts that might occur in vivo at high passages, be-
cause osteoblasts in culture dedifferentiate to a ﬁbroblast
phenotype at medium passages.
Bone from the right iliac crest biopsy had normal his-
tology (ﬁg. 2A–2D). Under polarized light, the toluidine-
blue–stained specimen showed well-organized lamellae
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Table 3
Osteoblast Results from 32P-Labeled PCR Assay of




% OF OSTEOBLASTS HETEROZYGOUS FOR




Left Side Right Side
P1 96  2 b … 49  4 (50)
P2 … … 40  3 (41)
P3 97  1 71  2 (73) 37  5 (39)
P5 97  3 71  7 (73) …
P7 90  2 65  12 (73) …
P10 95  7 39  6 (41) …
NOTE.—Genomic DNA of COL1A1 was ampliﬁed for
exon 19–intron 19 (174 bp).
a Value calculated by densitometry of DdeI-digested PCR
fragments as follows: digested fragments/total fragments#
2 # 100.
b P1 Osteoblast DNA was used to normalize P1–P2 mo-
saic carrier cells.
Table 4
Osteoblast Results from Single-Cell PCR Assay of Samples from the Mosaic Carrier of OI Type IV and Affected Son
NO. OF CELLS DETECTED IN
Mosaic Carrier
Heterozygous Affected Son Left Side Right Side
PASSAGE NO. Normal Mutant Heterozygous Total %a Normal Mutant Heterozygous Total %a Normal Mutant Heterozygous Total %a
P1 … … … … … … … … … … 67 0 39 106 48.1
P3 12 0 93 105 88.6 36 0 66 102 73.0 69 0 39 108 47.2
P10 12 0 90 102 88.2 52 1 50 103 61.2 … … … … …
a Percentage of heterogeneous cells plus mutant cells, divided by the total number of cells. (In the mosaic carrier, this number has been normalized for false-
normal cells in the affected son.)
around their respective osteocytes. Bone volume and
bone volume per total volume were normal.
The second mosaic carrier analyzed was a 67-year-old
woman. Two of her seven children had severe OI type
III. One affected son died of pneumonia as a child. The
second affected son is now 46 years old and has a 17-
year-old daughter with severe OI. On physical exam, the
carrier had normal height (161 cm; 50th percentile for
adult women) and well-proportioned span (158 cm).
Her upper-to-lower segment ratio was 0.90, which is
within the normal range (1.5 SDs for adult women).
The only manifestations of a connective tissue disorder
were blue sclerae and a triangular-shaped facies. She had
never sustained a fracture. She died of pneumonia after
an intracranial hemorrhage at age 67 years; tissues taken
at autopsy and embedded in parafﬁn for histology anal-
ysis were available.
The type I collagen mutation causing OI type III in
this family has been published (Wang et al. 1996). It is
a gene deletion of 562 bp in the genomic DNA of one
COL1A1 allele, which results in the deletion of exons
33–36. PCR screening of family members by Wang and
colleagues revealed that the mosaic carrier had a high
proportion of leukocytes heterozygous for the mutant
allele.
DNA was extracted from parafﬁn-embedded autopsy
tissues, cultured P5 ﬁbroblasts, and leukocytes of the mo-
saic carrier of OI type III, with informed consent of her
family, by use of the Puregene DNA Puriﬁcation Kit. A
32P-labeled multiplex PCR assay (ﬁg. 3) was developed,
which allowed quantitation of the proportions of the two
COL1A1 alleles. Allele ratios were calculated and then
doubled for the proportion of heterozygous cells.
The mosaic carrier had ∼60% mutant leukocytes and
∼45% mutant ﬁbroblasts (data not shown). By use of
the autopsy samples of type-I-collagen–rich tissues (ﬁg.
3), we determined that 65% of cells were heterozygous
for the collagen deletion in tracheal ring, aorta, and lung.
In the skeletal system, ∼40% of calvarial cells (∼20%
of alleles) carried the collagen mutation. We assumed
for our calculations that the DNA was derived from
osteoblasts and osteocytes in the calvarial sample, but
the presence of other cells in the autopsy tissue cannot
be excluded.
Histology of bone from rib and calvarium was normal
for a woman of the carrier’s age (ﬁg. 2E and 2F). The
trabeculae were of normal number and width, with well-
organized lamellae. Likewise, histology of skin, tracheal
ring, and aorta showed well-organized connective tissues
(ﬁg. 2G–2I). An aggressive inﬁltrative process compatible
with her pneumonia distorts the lung histology (ﬁg. 2J).
Mosaic carriers occur in a wide range of dominant
genetic disorders, including skeletal dysplasias (Gottlieb
et al. 2001; Youssouﬁan and Pyeritz 2002). These car-
riers have distinct mutant and normal cell lines in so-
matic and/or germline tissues. In OI, mosaic-carrier in-
dividuals are most commonly identiﬁed when they have
more than one child with clinically signiﬁcant disease.
The mosaic carriers themselves do not usually come to
medical attention before they have affected children, be-
cause their phenotypes range from clinically normal to
minimally affected. Some mosaic carriers have physical
ﬁndings, such as blue sclerae, dentinogenesis imperfecta,
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Figure 2 Histology of tissues from both mosaic carriers. A–C,
Biopsy of the iliac crest sample from the mosaic carrier of OI type IV.
A and B, Toluidine-blue–stained section under normal and polarized
light. C, von Kossa stained section, with normal bone volume. D,
Quantitative histomorphometry of sample in panelC. E and F, Sections
of calvarial and rib bone, respectively, of the mosaic carrier of OI type
III, stained with hematoxylin-eosin. G–J, Sections of dermis, tracheal
ring, aorta wall, and lung, respectively, of the mosaic carrier of OI
type III, stained with hematoxylin-eosin.
shorter stature than same-gender siblings, or a medical
history that includes one to several fractures. Some mo-
saic carriers have a clinical course similar to the mildest
end of the OI severity range. However, mosaic carriers
do not have an intermediate form of the severe skeletal
disorder seen in their own children. The mild clinical
condition of mosaic carriers might be due to a low pro-
portion of cells carrying the collagenmutation in skeletal
tissues, resulting from the fortuitous distribution of the
daughter cells of the original mutant cell line or from
slower growth of mutant cells. Alternatively, the mild
clinical condition of mosaic carriers might result from a
high threshold for the structural effects of mutant col-
lagen in the extracellular matrix. The proportion of mu-
tant osteoblasts compatible with the mild or normal clin-
ical status of OI mosaic carriers has not been determined.
Mosaic carriers are medically signiﬁcant because they
are the natural model for mesenchymal cell therapy.
Mesenchymal stem cells (MSCs) are multipotential cells
isolated from bone marrow that can differentiate into
osteoblasts, chondrocytes, myoblasts, and adipocytes
(Prockop 1997). Patients treated with cell therapywould
become somatic mosaics of their own heterozygous cells
and normal donor cells. Transplantation of MSCs into
mice (Pereira et al. 1998; Oyama et al. 1999), fetal lambs
(Mackenzie and Flake 2001), and baboons (Devine et
al. 2001) has resulted in the uptake of low levels of donor
cells into bone marrow or tissue, which is detectable by
PCR, GFP, or CAT assays. MSC therapy of ﬁve children
with severe OI resulted in a 1%–2% donor cell skeletal
engraftment (Horwitz et al. 1999) and reports of tran-
sient clinical improvement (Marini 1999; Horwitz et al.
2001). Because some mosaic carriers of OI have hetero-
zygosity of virtually all ﬁbroblasts, it was speculated that
only a very small percentage of normal-cell engraftment
would be required for successful therapy (Gerson 1999).
We have determined the proportion of mutant oste-
oblasts in two mosaic carriers for OI and correlated this
data with the clinical exam and bone histology. We dem-
onstrated that normal or mildly decreased skeletal func-
tion is compatible with a substantial burden of mutant
cells. The mildly affected carrier of OI type IV has 50%–
75% mutant osteoblasts, depending on body side. The
clinically normal carrier of severe OI type III had 40%
mutant osteoblasts in her calvarium and ∼65% mutant
cells in collagen-rich connective tissues, such as aorta,
tracheal ring, dermis, and lung. To approximate the
growth competition experienced by the mutant cells in
vivo, the cultured cells of the type IV carrier were ex-
amined over multiple passages. In both ﬁbroblasts and
osteoblasts, the proportion of mutant cells was stable
over multiple passages, with only modest decline in the
proportion of mutant cells at high passages, showing
that these mutant cells have normal rates of cell division
in culture. Previously, the proportion of mutant cells in
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Figure 3 Multiplex PCR of autopsy tissues of the mosaic carrier of OI type III. A, Diagram of multiplex PCR ampliﬁcation of DNA
from autopsy tissues of the mosaic carrier. The normal allele sense primer spanned the exon 36/intron 36 junction (5′-TGGCCCCCCTgtgagtaccaa-
gacccccat-3′ [lowercase letters denote intron nucleotides; uppercase letters denote exon nucleotides]), and the mutant allele sense primer spanned
the novel junction between exon 34 and the retained portion of intron 36 (5′-CCTGCTGGTGCCCCTGGTGACggaa-3′).The common antisense
primer (5′-CGAGCACCTTTGGCTCCAGGAGCACCAACA-3′) is in exon 38. B, Allele speciﬁcity of PCR primers, veriﬁed using subcloned
mutant (M) and normal (N) proband DNA. Only the speciﬁc normal COL1A1 allele (459 bp) and mutant allele (410 bp) products were detected
by the respective sense primers. C, A 32P-labeled standard curve (200 ng DNA/sample), prepared by mixing genomic DNA from normal leukocytes
with DNA from the heterozygous leukocytes of the carrier’s affected son. PCR reactions used 200 ng genomic DNA, 1 U Platinum Taq DNA
Polymerase High Fidelity (Invitrogen), and 5 mCi of 111 TBq/mmol [a-32P] dCTP. Normal and mutant allele products have similar numbers of
C nucleotides, 132 and 120, respectively; preferential ampliﬁcation of the mutant allele product is presumably due to differences in secondary
structure, as well as smaller size. D, The PCR standard curve, quantitated by densitometry, and the proportion of mutant ampliﬁcation product
for each allele ratio in the standard curve. E and F, PCR ampliﬁcation products of DNA from various autopsy tissues of the mosaic carrier.
The normal allele product (459 bp) and the mutant allele product (410 bp) are indicated. Allele ratios were quantitated by densitometry and
normalized to the standard curve.
the cultured ﬁbroblasts of two mosaic carriers for lethal
OI type II (Constantinou et al. 1989; Cohen-Solal et al.
1996) was reported to decrease by one or two orders of
magnitude at high passage numbers compared with low
passage numbers. Despite the high proportion of cells
synthesizing mutant collagen, both women had skeletal
growth within the normal population range. The carrier
of OI type IV had moderately shorter stature than pre-
dicted by parental heights, but she had a short trunk,
which is less typical of OI than are short legs. She also
had normal lumbar spine (L1–L4) results, as measured
by DEXA. Furthermore, bone histology was normal for
her age.
We infer from our data that mutant collagen can be
incorporated to a high level without detriment to his-
tology and density and with only modest detriment to
bone growth and strength. These data suggest that there
is a threshold, rather than a linear effect, for the mutant
matrix components and that features of mild OI are not
noted until the threshold level of mutant collagen is ex-
ceeded. Since the carrier of OI type IV has a moderately
short stature, radiographic dentinogenesis imperfecta,
hearing loss, and two minor fractures, her mutation bur-
den may be at or near the functional threshold.
Our data provide the ﬁrst quantitation of the pro-
portion of heterozygous cells in the skeletal system of
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mosaic carriers for moderate and severe types of OI.
Other mosaic carriers may have a lower level of mutant
osteoblasts because the embryonic mutation was dis-
tributed to only a few skeletal precursors. These low-
percentage mosaic carriers are not informative for the
maximum level of osteoblasts compatible with normal
skeletal functioning. Still other mosaic carriers may have
a higher level of mutant osteoblasts, supporting the con-
clusion that transplantation of only a small percentage
of normal osteoblast precursors would be clinically ben-
eﬁcial. Until data from additional rare mosaic-carrier
bone samples are available, the data from the carriers
presented in this study can be used to tentatively set the
goal for gene therapy by MSC transplant at 30%–60%
normal osteoblasts. It should be noted that we have ex-
amined mosaic carriers for the severe and moderate
(types III and IV, respectively) forms of OI. A higher
proportion of uptake of normal donor cells might be
required if the recipient were heterozygous for a collagen
mutation that caused the lethal (type II) form of OI,
since the threshold of functional expression might be
lower with increased disease severity. Furthermore, in
our cases we found minimal selection against ﬁbroblasts
or osteoblasts carrying the collagen mutations. For some
collagen mutations, normal cells might have a selective
advantage. In these cases, uptake of 5% normal cells
could gradually result in normal cells comprising30%
of the bone cell population. Thus, the proportion of
normal osteoblasts needed for proper skeletal function-
ing could be achieved either directly, by uptake of trans-
planted stem cells, or gradually, by selective advantage
of normal cells.
The distribution of mutant and normal cells within
mosaic-carrier tissue may contribute to normal function.
The proportion of mutant osteoblasts in the carrier of
OI type IV differs by 25% between body sides. This
difference may result from clustering of the daughter
cells of normal and mutant osteoblasts. Daughter cells
from an MSC transplant might also have a patchy dis-
tribution. CAT-taggedMSCs were distributed in isolated
lacunae in mouse bones 1 mo after transplantation (Hou
et al. 1999). This pattern could provide a functional
advantage because ﬁbrils are assembled in the pericel-
lular matrix. Local collections of normal cells in mosaic-
carrier bone would result in regional pockets of almost-
normal matrix that could increase the overall mechanical
strength. Nonetheless, transplantation of even modest
levels of normal osteoblast precursors remains a signif-
icant challenge. Selection of osteoblast precursors at a
particular developmental stage or elucidation of physi-
ological homing signals for bone precursor cells may
enhance the percentage of transplanted cells taken up
by bone tissue. Furthermore, normal cells need to be
distributed throughout bone to enhance mechanical
properties. This factor favors transplantation of osteo-
blast precursors during the higher–bone-turnover period
of early childhood.
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